Back to top

CRNX Downgraded by UBS -- Price Target Raised to $85.00

CRNX Downgraded by UBS -- Price Target Raised to $85.00

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Crinetics Pharmaceuticals, Inc. (CRNX)